These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8114 related articles for article (PubMed ID: 1497699)

  • 1. Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor--and kringle one-domains.
    Emeis JJ; Verheijen JH
    Arzneimittelforschung; 1992 Mar; 42(3):358-62. PubMed ID: 1497699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
    Collen D; Stassen JM; De Cock F
    Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergism between tissue-type plasminogen activator and a genetically engineered variant lacking the finger domain, the growth factor domain and the first kringle domain.
    Mattson C; Wikström K; Sterky C; Pohl G
    Thromb Haemost; 1991 Mar; 65(3):286-90. PubMed ID: 1710837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells.
    Collen D; Stassen JM; Marafino BJ; Builder S; De Cock F; Ogez J; Tajiri D; Pennica D; Bennett WF; Salwa J
    J Pharmacol Exp Ther; 1984 Oct; 231(1):146-52. PubMed ID: 6541693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombolytic activity of two chimeric recombinant plasminogen activators (FK2tu-PA and K2tu-PA) in rabbits.
    Agnelli G; Pascucci C; Colucci M; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1992 Sep; 68(3):331-5. PubMed ID: 1440500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
    Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA.
    Heeremans JL; Prevost R; Bekkers ME; Los P; Emeis JJ; Kluft C; Crommelin DJ
    Thromb Haemost; 1995 Mar; 73(3):488-94. PubMed ID: 7667833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A hybrid plasminogen activator binds to the u-PA receptor and has a reduced thrombolytic potency in vivo.
    Asselbergs FA; Bürgi R; Hamerman J; Heim J; van Oostrum J; Agnelli G
    Thromb Haemost; 1993 Jan; 69(1):50-5. PubMed ID: 8383359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis.
    Collen D; Stassen JM; Blaber M; Winkler M; Verstraete M
    Thromb Haemost; 1984 Aug; 52(1):27-30. PubMed ID: 6541817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small animal thrombosis models for the evaluation of thrombolytic agents.
    Stassen JM; Lijnen HR; Kieckens L; Collen D
    Circulation; 1991 Jun; 83(6 Suppl):IV65-72. PubMed ID: 2040073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model.
    Collen D; Lijnen HR; Vanlinthout I; Kieckens L; Nelles L; Stassen JM
    Thromb Haemost; 1991 Feb; 65(2):174-80. PubMed ID: 1905070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
    Kaiser B; Fareed J
    Thromb Haemost; 1996 Oct; 76(4):615-20. PubMed ID: 8903005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo.
    Vaughan DE; Declerck PJ; Van Houtte E; De Mol M; Collen D
    Thromb Haemost; 1992 Jul; 68(1):60-3. PubMed ID: 1514173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of potentiation with murine antiplatelet GPIIb/IIIa antibody of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in a canine venous thrombosis model.
    Spriggs D; Gold HK; Hashimoto Y; Van Houtte E; Vermylen J; Collen D
    Thromb Haemost; 1989 Feb; 61(1):93-6. PubMed ID: 2501892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrin affinity and clearance of t-PA deletion and substitution analogues.
    Johannessen M; Diness V; Pingel K; Petersen LC; Rao D; Lioubin P; O'Hara P; Mulvihill E
    Thromb Haemost; 1990 Feb; 63(1):54-9. PubMed ID: 2111048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant variants of tissue-type plasminogen activator containing amino acid substitutions in the finger domain.
    Yahara H; Matsumoto K; Maruyama H; Nagaoka T; Ikenaka Y; Yajima K; Fukao H; Ueshima S; Matsuo O
    Thromb Haemost; 1992 Dec; 68(6):672-7. PubMed ID: 1287881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A thrombosis model for evaluating thrombolytic agents in the guinea-pig: comparison of t-PA, scu-PA and a novel thrombolytic agent, staphylokinase, on thrombolytic activity.
    Hirata Y; Umemura K; Takiguchi Y; Uematsu T; Nakashima M
    Blood Coagul Fibrinolysis; 1993 Aug; 4(4):569-75. PubMed ID: 7692999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
    Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
    Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 406.